J&J pitch­es its S1P1 MS drug in­to the reg­u­la­to­ry ring as the com­pe­ti­tion heats up fast

The S1P1 ri­val­ry in the mul­ti­ple scle­ro­sis are­na is about to heat up sub­stan­tial­ly.

Six months af­ter beat­ing out Auba­gio in a head-to-head study, J&J has teed up its mar­ket­ing ap­pli­ca­tion for pones­i­mod. If ap­proved the drug, a big prize in their $30 bil­lion Acte­lion buy­out, will go up against No­var­tis’ ri­val Mayzent as well as ozan­i­mod from Bris­tol My­ers — which is fac­ing a loom­ing PDU­FA date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER